Newswire (Published: Thursday, January 10, 2019, 10:00:00 AM CST, Received: Thursday, January 10, 2019, 10:29:46 AM CST)

Word Count: 430

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating in New Haven, Connecticut, by NewsRx journalists, research stated, "A variety of treatment modalities are available for the management of clinically localized prostate cancer in the United States. In addition to clinical factors, treatment modality choice may be influenced by a patient's insurance status."

The news reporters obtained a quote from the research from Yale University, "Using a national data set, we investigated the relationship between insurance status and prostate cancer treatment modality selection among nonelderly men in the United States. Nonelderly men age 18 to 64 years treated for localized prostate cancer from 2010 to 2014 were identified within the National Cancer Database. Patients with no insurance, Medicaid, or private insurance were included. The chi(2) and multivariable logistic regression analyses were used to evaluate the association of insurance status, other demographic and facility factors, and D'Amico risk classification with treatment modality. We identified 135,937 patients with either no insurance (2.8%), Medicaid (4.2%), or private insurance (92.9%) treated for prostate cancer who underwent cancer-directed treatment or active surveillance between 2010 and 2014. Patients with private insurance were more likely to receive minimally invasive surgery (61.4% vs. 35.4%, respectively; P<0.001) and less likely to receive external beam radiotherapy (10.9% vs. 26.9%, respectively; P<0.001) than patients with no insurance. On multivariable analysis, among patients with no insurance and private insurance, private insurance was the strongest predictor of receipt of minimally invasive surgery (adjusted odds ratio, 2.61; 95% confidence interval, 2.44-2.79; P<0.001)."

According to the news reporters, the research concluded: "Insurance status is a strong predictor of prostate cancer treatment modality among nonelderly men in the United States."

For more information on this research see: Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal of Clinical Oncology-Cancer Clinical Trials, 2018;41(11):1062-1068. American Journal of Clinical Oncology-Cancer Clinical Trials can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA (see also Oncology - Prostate Cancer).

Our news correspondents report that additional information may be obtained by contacting T.J. Bledsoe, Yale University, Sch Med, Dept. of Therapeut Radiol, New Haven, CT 06510, United States. Additional authors for this research include H.S. Park, C.E. Rutter, S. Aneja, P.L. Nguyen and J.B. Yu.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Yale University
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Industries

Healthcare
      Healthcare Services
            Managed Care Services
Insurance
      Health Insurance
            Medical Insurance

Places

North America
United States
Americas
Connecticut
Pennsylvania
New Haven
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Healthcare Management